Ocugen Inc Stock Performance
| OCGN Stock | USD 1.18 0.07 5.60% |
Ocugen holds a performance score of 14 on a scale of zero to a hundred. The company holds a Beta of 2.33, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Ocugen will likely underperform. Use Ocugen downside variance, as well as the relationship between the accumulation distribution and price action indicator , to analyze future returns on Ocugen.
Risk-Adjusted Performance
14 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Ocugen Inc are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of very weak technical and fundamental indicators, Ocugen displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:60 | Dividend Date 2019-09-30 | Last Split Date 2019-09-30 |
1 | Disposition of tradable shares by Qamar Huma of Ocugen subject to Rule 16b-3 | 03/18/2024 |
2 | Ocugen Q4 2023 Earnings Call Transcript | 04/02/2024 |
3 | OCUGEN LOSS ALERT ROSEN, LEADING INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Inquire About Securities Class Action Investigation OCGN | 04/10/2024 |
4 | Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets | 04/12/2024 |
5 | Acquisition by Qamar Huma of 308465 shares of Ocugen at 1.59 subject to Rule 16b-3 | 04/16/2024 |
6 | SHAREHOLDER NOTICE Faruqi Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen | 04/17/2024 |
7 | ROSEN, A TOP RANKED LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm O... | 04/18/2024 |
8 | Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 12 ArMaDa Clinical Trial of OCU410A Modifier Gene Therapy | 04/19/2024 |
9 | INVESTOR DEADLINE APPROACHING Faruqi Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen | 04/23/2024 |
| Begin Period Cash Flow | 77.6 M |
Ocugen |
Ocugen Relative Risk vs. Return Landscape
If you would invest 54.00 in Ocugen Inc on January 26, 2024 and sell it today you would earn a total of 64.00 from holding Ocugen Inc or generate 118.52% return on investment over 90 days. Ocugen Inc is currently generating 1.6328% in daily expected returns and assumes 8.7655% risk (volatility on return distribution) over the 90 days horizon. In different words, 77% of stocks are less volatile than Ocugen, and 68% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ocugen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ocugen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ocugen Inc, and traders can use it to determine the average amount a Ocugen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1863
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | OCGN | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 8.77 actual daily | 77 77% of assets are less volatile |
Expected Return
| 1.63 actual daily | 32 68% of assets have higher returns |
Risk-Adjusted Return
| 0.19 actual daily | 14 86% of assets perform better |
Based on monthly moving average Ocugen is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ocugen by adding it to a well-diversified portfolio.
Ocugen Fundamentals Growth
Ocugen Stock prices reflect investors' perceptions of the future prospects and financial health of Ocugen, and Ocugen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ocugen Stock performance.
| Return On Equity | -1.1 | ||||
| Return On Asset | -0.47 | ||||
| Operating Margin | (1.43) % | ||||
| Current Valuation | 289.14 M | ||||
| Shares Outstanding | 257.32 M | ||||
| Price To Earning | (1.81) X | ||||
| Price To Book | 7.51 X | ||||
| Price To Sales | 25,069 X | ||||
| Revenue | 6.04 M | ||||
| Gross Profit | (49.76 M) | ||||
| EBITDA | (64.83 M) | ||||
| Net Income | (63.08 M) | ||||
| Cash And Equivalents | 101.6 M | ||||
| Cash Per Share | 0.46 X | ||||
| Total Debt | 6.94 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 7.21 X | ||||
| Book Value Per Share | 0.16 X | ||||
| Cash Flow From Operations | (62.05 M) | ||||
| Earnings Per Share | (0.26) X | ||||
| Market Capitalization | 321.66 M | ||||
| Total Asset | 64.55 M | ||||
| Retained Earnings | (286.17 M) | ||||
| Working Capital | 25.88 M | ||||
| Current Asset | 17.53 M | ||||
| Current Liabilities | 4.21 M | ||||
About Ocugen Performance
To evaluate Ocugen Inc Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Ocugen generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Ocugen Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Ocugen Inc market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Ocugen's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.00 | 0.00 | |
| Return On Tangible Assets | (0.98) | (1.03) | |
| Return On Capital Employed | (1.38) | (1.45) | |
| Return On Assets | (0.98) | (1.03) | |
| Return On Equity | (1.56) | (1.48) |
Things to note about Ocugen Inc performance evaluation
Checking the ongoing alerts about Ocugen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ocugen Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ocugen Inc is way too risky over 90 days horizon | |
| Ocugen Inc may become a speculative penny stock | |
| Ocugen Inc appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 6.04 M. Net Loss for the year was (63.08 M) with loss before overhead, payroll, taxes, and interest of (49.76 M). | |
| Ocugen Inc currently holds about 101.6 M in cash with (62.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.46. | |
| Ocugen Inc has a poor financial position based on the latest SEC disclosures | |
| Latest headline from benzinga.com: INVESTOR DEADLINE APPROACHING Faruqi Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen |
- Analyzing Ocugen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ocugen's stock is overvalued or undervalued compared to its peers.
- Examining Ocugen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ocugen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ocugen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ocugen's stock. These opinions can provide insight into Ocugen's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocugen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Ocugen Inc information on this page should be used as a complementary analysis to other Ocugen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Complementary Tools for Ocugen Stock analysis
When running Ocugen's price analysis, check to measure Ocugen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ocugen is operating at the current time. Most of Ocugen's value examination focuses on studying past and present price action to predict the probability of Ocugen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ocugen's price. Additionally, you may evaluate how the addition of Ocugen to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |
Is Ocugen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocugen. If investors know Ocugen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocugen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.26) | Revenue Per Share 0.025 | Quarterly Revenue Growth 1.426 | Return On Assets (0.47) | Return On Equity (1.10) |
The market value of Ocugen Inc is measured differently than its book value, which is the value of Ocugen that is recorded on the company's balance sheet. Investors also form their own opinion of Ocugen's value that differs from its market value or its book value, called intrinsic value, which is Ocugen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocugen's market value can be influenced by many factors that don't directly affect Ocugen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocugen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocugen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocugen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.